Esomeprazole Tablets Versus Solution After Gastric Bypass Surgery
Tests esomeprazole as tablets or liquid on stomach acid in adults after bypass.
Plain-language title generated from the registry record
Registry title: The Bioavailability and Effect on Pouch pH of Esomeprazole After Gastric Bypass
Key facts
- Where
- Schlieren, SwitzerlandSee the site
- Phase
- Phase 4
Where in Switzerland
- Spital LimmattalSchlieren, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Prof Urs Zingg
- Trial code
- NCT05320796
- Record updated
- 9 June 2026
- Original description
The objective of this study is to investigate the effect of Esomeprazol administered in tablets (Esomeprazol MUT Sandoz® 40mg) or in solution (Esomeprazol MUT Sandoz® 40mg in 10ml tap water) on acid production in the gastric pouch by measuring the intragastric pH and the serum concentration of esomeprazole.Read full original descriptionShow less
The Bioavailability and Effect on Pouch pH of Esomeprazole as Tablets or in Solution After Laparoscopic Proximal RYGB for Morbid Obesity - an Investigator Blinded Pilot Study
The objective of this study is to investigate the effect of Esomeprazol administered in tablets (Esomeprazol MUT Sandoz® 40mg) or in solution (Esomeprazol MUT Sandoz® 40mg in 10ml tap water) on acid production in the gastric pouch by measuring the intragastric pH and the serum concentration of esomeprazole.
Inclusion: Proximal Roux-en-Y gastric bypass with linear stapled anastomosis 12 months prior to the study investigation; Routine administration of proton pump inhibitors for 6 months postoperatively; No intake of proton pump inhibitors at least 4 weeks prior to study investigation; No marginal ulcers in upper endoscopy prior to placement of wireless BRAVO™ pH monitoring capsule; No symptoms related to gastro-esophageal reflux or marginal ulcers (i.e. epigastric pain, retrosternal burning, regurgitation); Informed consent as documented by signature.
Exclusion: Known intolerance or allergy for Esomeprazol; Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant; Contraindication for upper endoscopy; Women who are pregnant or breast feeding Major hepatic dysfunction.